Patten & Patten Inc. TN Buys 3,147 Shares of DexCom, Inc. (NASDAQ:DXCM)

Patten & Patten Inc. TN increased its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 4.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 77,958 shares of the medical device company's stock after purchasing an additional 3,147 shares during the period. Patten & Patten Inc. TN's holdings in DexCom were worth $5,324,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Forvis Mazars Wealth Advisors LLC raised its position in shares of DexCom by 0.7% during the 4th quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock valued at $1,359,000 after acquiring an additional 118 shares during the last quarter. Principal Securities Inc. raised its position in shares of DexCom by 3.4% during the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock valued at $316,000 after acquiring an additional 135 shares during the last quarter. Larson Financial Group LLC raised its position in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares during the last quarter. Nia Impact Advisors LLC raised its position in shares of DexCom by 1.4% during the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock valued at $766,000 after acquiring an additional 140 shares during the last quarter. Finally, Level Four Advisory Services LLC raised its position in shares of DexCom by 1.1% during the 4th quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock valued at $1,026,000 after acquiring an additional 150 shares during the last quarter. Institutional investors own 97.75% of the company's stock.

DexCom Stock Up 0.2%

Shares of DexCom stock traded up $0.13 during trading hours on Thursday, reaching $85.74. 2,394,712 shares of the company's stock were exchanged, compared to its average volume of 4,339,412. The company has a 50 day moving average of $75.64 and a two-hundred day moving average of $78.89. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $118.80. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The stock has a market cap of $33.62 billion, a P/E ratio of 59.96, a P/E/G ratio of 2.30 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. The business had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same quarter in the prior year, the company earned $0.32 earnings per share. The company's quarterly revenue was up 12.5% on a year-over-year basis. On average, sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DXCM has been the subject of several recent research reports. Morgan Stanley upped their target price on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. The Goldman Sachs Group initiated coverage on shares of DexCom in a research report on Friday, May 30th. They set a "buy" rating and a $104.00 target price for the company. Barclays upped their target price on shares of DexCom from $90.00 to $93.00 and gave the company an "equal weight" rating in a research report on Monday, May 5th. Piper Sandler dropped their target price on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research report on Friday, May 2nd. Finally, Robert W. Baird lowered their price objective on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Five analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, DexCom currently has a consensus rating of "Moderate Buy" and an average price target of $98.32.

Insider Transactions at DexCom

In other news, EVP Michael Jon Brown sold 10,000 shares of the company's stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $84.28, for a total value of $842,800.00. Following the sale, the executive vice president now directly owns 95,602 shares of the company's stock, valued at approximately $8,057,336.56. This represents a 9.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jereme M. Sylvain sold 7,000 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the completion of the sale, the executive vice president now directly owns 135,482 shares in the company, valued at approximately $10,002,636.06. The trade was a 4.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 83,110 shares of company stock worth $6,103,505 in the last three months. Insiders own 0.32% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.